FOLFOX4 After Surgery Improves Overall Survival In Patients With Early Colon Cancer

Armen Hareyan's picture

FOLFOX4, an Eloxatin (oxaliplatin injection)-based chemotherapy regimen, significantly improved the overall survival of patients with surgically resected

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.